The Internet Journal of Infectious Diseases™ ISSN: 1528-8366

| Home | Editors | Current Issue | Archives | Instructions for Authors | Disclaimer | Bookmark and Share Share with others |
 

Intrathecal Colistin For Treatment Of Acinetobacter Spp Meningitis: Case Report

Sevtap Hekimoglu Sahin MD
Anaesthesia Dr.
Department of Anaesthesia and Reanimation
Trakya Univ. Medical Faculty Email address Physical Address

Aygul Selik MD
Infection Dr.
Department of Infection
Trakya Univ. Medical Faculty Physical Address

Dilek Memis MD
Associate Professor
Department of Anaesthesiology
Trakya Univ. Medical Faculty Physical Address

Citation: S. H. Sahin, A. Selik & D. Memis : Intrathecal Colistin For Treatment Of Acinetobacter Spp Meningitis: Case Report . The Internet Journal of Infectious Diseases. 2008 Volume 6 Number 2

Keywords: Colistin | infection | nosocomial | CNS infections | meningitis

 

Abstract

We report a case of meningitis caused by a multiresistant gram-negative rod that was successfully treated with intrathecal colistin.
A 30-year-old boy who had a car accident required hospitalization, including decompressive craniectomy and placement of an external ventricular drainage catheter. Cerebrospinal fluid and blood cultures demonstrated Acinetobacter spp. Intravenous colistin was initiated initially but there was no change in the patient's clinical situation. Therapy was added to intrathecal colistin 5 mg/day via the external ventricular drainage catheter, and cerebrospinal fluid cultures were followed to assess efficacy.
Our experience shows that intrathecal colistin is a safe and curative treatment drug for multidrug-resistant Acinetobacter spp menengitis.


Introduction

In a large series of adults with acute bacterial meningitis Acinetobacter spp. were found to be responsible for approx. 10% of Gram negative bacillary and 4% of all nosocomial meningitides(1) Treatment of meningitis due to multi-drug resistant Acinetobacter spp. can be difficult. Colistin, an antibiotic first discovered almost 60 years ago, has not been used greatly since the early 1980s because of its nephrotoxicity, except in patients with cystic fibrosis (2,3). However, it has been reintroduced recently in clinical practice as a last resort for treatment of nosocomial infections caused by multiresistant bacteria (4,5). In this report we describe the use of intrathecal colistin for treatment of multidrug-resistant Acinetobacter spp menengitis meningitis therapy.

Case Report

A 30-year-old boy who had a car accident required hospitalization, including decompressive craniectomy and placement of an external ventricular drainage catheter. The patient was not on any medication, had no history of alcohol abuse and had an unremarkable medical record. He transferred intensive care unit and respiratory support was started. His physical examination during admission was fever (38.10C), heart (100/min) rates, decreased arterial blood pressure (100/50 mmHg). Leukocyte count 13.21 mm3, hemoglobin 12.7 g/dl, haematocrit 37.5 %, platelet 272.000 mm3, electrolytes were normal. He was treated with intravenous kolloid and crystolloid infusion, dopamine 5 ?g/kg/min. and antipyretic. Cerebrospinal fluid and blood cultures demonstrated Acinetobacter spp. Intravenous colistin was initiated initially but there was no change in the patient's clinical situation. Therapy was added to intrathecal colistin 5 mg/day via the external ventricular drainage catheter, and cerebrospinal fluid cultures were followed to assess efficacy. The patient had a successful outcome. Three weeks after finishing the intrathecal treatment, the patient underwent the last drainage with no complications.

Discussion

Some cases of bacterial meningitis cannot always be treated intravenously with conventional antimicrobial agents. Inadequate therapy for infections acquired in the intensive care unit (ICU) is associated with increased mortality (6), but the frequent use of broad-spectrum antibiotics means that the ICU environment has become a theatre for selection of multiresistant microorganisms. Infections caused by multiresistant Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter spp. have become a serious problem worldwide (7). Patients with meningitis due to multiresistant gram-negative rods should be treated intrathecally with polymixin B or colistin used. Multiresistant Acinetobacter spp. are frequently the etiologic agent of nosocomial infections, and 90% of these strains are susceptible to colistin. We used intrathecal colistin 5 mg/day for 21 days for the treatment of multidrug-resistant Acinetobacter spp .and succeeded without any side effects.

Renal injury is the major adverse effect of colistin. In the largest study to date, published in 1970, frequently reversible renal impairment was found in 20% of patients receiving colistin (8). This possibility of renal toxicity should be considered seriously, especially when colistin is used as a last resort in patients prone to renal dysfunction because of illness severity and ? or sepsis. However, renal function impairment should not be attributed solely to colistin toxicity as other factors, e.g., the development of septic shock and multi-organ failure, may also make a significant contribution. Indeed, previous studies have shown that advanced age, severe sepsis, major surgery, low cardiac output syndrome and hypovolaemia are all common conditions associated with acute renal failure in the ICU setting (9,10,11). Renal function impairment were not development in our patient.

John et al (12) reported intraventricular or intrathecal colistin is effective and well tolerated apart from reversible chemical meningitis/ventriculitis and should be considered for Multidrug-resistant Acinetobacter baumannii (MRAB) CNS infection.

In conclusion, intrathecal colistin appears to be relatively safe and effective in treating severely ill ICU patients with infections caused by multiresistant Gram-negative bacteria. Clinicians should be vigilant for renal function deterioration during colistin therapy

Correspondence address

Anaesth Dr Sevtap Hekimoglu Sahin
Trakya University Medical Faculty,
Department of Anaesthesiology and Reanimation,
22030, Edirne, TURKEY
Tel No : 0 90 284 2357641/3200
Fax No: 0 90 284 2358096
E-mail. [sevtaphekimoglu@mynet.com]

References

1. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness Jr VS, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328(1):21-8. (s)

2. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in vitro activity of colistin sulfomethate sodium. J Antimicrob Chemother 1997; 39: 255- 260. (s)

3. Horton J, Pankey GA. Polymyxin B, colistin and sodium colistimethate. Med Clin North Am 1982; 66: 135-142. (s)

4. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulfomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-993. (s)

5. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: 78-83. (s)

6. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 432-474. (s)

7. Livermore D. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640. (s)

8. Koch-Weser G, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Ann Intern Med 1970; 72: 857-868. (s)

9. Uchino S, Doig GS, Bellomo R et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32: 1669-1677. (s)

10. De Mendonca A, Vincent JL, Suter PM et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intens Care Med 2000; 26: 915-921. (s)

11. A. S. Michalopoulos, S. Tsiodras, K. Rellos, S. et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121. (s)

12. John Ng, Iain B. Gosbell, John A. Kelly. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review Journal of Antimicrobial Chemotherapy (2006) 58, 1078-1081. (s)

This article was last modified on Fri, 13 Feb 09 13:38:45 -0600

This page was generated on Mon, 22 Mar 10 07:43:38 -0500, and may be cached.
Advertisement